Spero Therapeutics is actively pursuing collaborations with non-commercial organizations and pharmaceutical partners for scientific expertise and funding support.
Since its founding, Spero has built strategic partnerships to advance its multi-asset, clinical-stage pipeline, raising over $65 million in committed non-dilutive funding since inception, with the potential to receive up to a total of $130 million in such funding, including potential milestone opportunities and full awards.
We intend to continue collaborating with government agencies, non-profit foundations and pharmaceutical partners to support the development of our product candidates.
Spero Therapeutics welcomes inquiries regarding potential opportunities for collaboration across discovery, development and commercialization.
For more information about partnership opportunities, contact us.
Stock information, SEC filings, corporate governance, IR resources and more.
Collaborative. Exciting. Challenging. Stimulating. Committed. Spero Therapeutics was founded in 2013.
